By Budi Oetomo Narendra 
This phenomenon, known as overdiagnosis, has long been considered one of the most significant potential drawbacks of population-based mammography screening programs. For decades, the precise frequency of overdiagnosis has been a subject of intense academic and clinical debate, with widely varying estimates fueling international discussions about the true balance between the benefits of early detection and the possible harms associated with screening. However, a groundbreaking new study has critically re-evaluated the existing evidence, particularly from randomized controlled trials, suggesting that previous high estimates of overdiagnosis may have been substantially overstated, offering a clearer and more reassuring picture for public health.
Historically, estimates from various randomized trials have differed sharply, with some prominent studies suggesting that a significant proportion—ranging from 30% to even 50%—of breast cancers detected through screening could fall into the category of overdiagnosis. These alarming figures have, for years, heavily influenced policy discussions, screening guidelines, and the public’s perception of mammography’s overall utility. They have prompted cautious approaches in many countries, leading to differing recommendations on screening age, frequency, and communication strategies with women. The potential for unnecessary anxiety, invasive biopsies, and overtreatment, including surgery, radiation, and chemotherapy, for cancers that would never have posed a threat, has been a central concern for medical professionals and patient advocates alike.
"The aim of our study was to bring together the evidence from all randomized controlled trials to get a clearer picture of the extent of overdiagnosis in breast cancer screening," stated Sisse Helle Njor, a professor at the University of Southern Denmark and Lillebælt Hospital, who was a lead author on the new analysis. She further elaborated on the implications of their findings: "Randomized trials have often been cited as evidence that overdiagnosis is a substantial problem. Our study shows that this interpretation is not as straightforward as it may seem." The research team’s comprehensive re-analysis now indicates that the additional breast cancer cases identified in these foundational randomized trials closely align with patterns observed in real-world settings, such as Denmark, where the rate of overdiagnosis linked to screening is estimated to be below 5%. This dramatic recalibration of the figures marks a pivotal moment in the ongoing discourse surrounding breast cancer screening.
Revisiting the Evidence: A New Look at Mammography Trials
To arrive at these revised estimates, the research team undertook a rigorous process: combining and reanalyzing results from all eight major randomized controlled trials of mammography screening ever conducted. These landmark trials included the New York Health Insurance Plan, Malmö, Two-County, Edinburgh, the Canadian National Breast Screening Study, Stockholm, Gothenburg, and UK Age. Each of these studies, initiated primarily between the 1970s and 1990s, played a crucial role in establishing the efficacy of mammography screening in reducing breast cancer mortality. However, their initial interpretations regarding overdiagnosis were often based on varying follow-up durations and methodological assumptions that, in retrospect, may have skewed the results.
The re-evaluation also involved a critical comparison with real-world data from Denmark. Denmark provided an invaluable reference point due to its staggered implementation of organized breast cancer screening programs. In some regions of Denmark, screening commenced as much as 17 years earlier than in others. This distinct chronological difference allowed researchers to meticulously track how breast cancer diagnoses changed immediately following the introduction of screening in a population and, crucially, how those patterns evolved over significantly longer periods. This "natural experiment" offered a unique opportunity to observe the long-term incidence trends that are essential for accurately distinguishing between true overdiagnosis and lead-time bias.
Professor Emerita Elsebeth Lynge from the Department of Public Health, University of Copenhagen, highlighted a key methodological nuance: "When screening is introduced, the number of breast cancer diagnoses initially rises because cancers are detected earlier than they would have been without screening. Over time, this should be followed by a drop, as some of these cancers would otherwise have been diagnosed later. This pattern can also be affected if women in either group continue to undergo screening after the trials had ended, which was common. If researchers do not take these factors into account, the initial increase can be mistaken for overdiagnosis." This crucial insight underpins the core of the new analysis: understanding the temporal dynamics of cancer incidence in screened versus unscreened populations is paramount. Previous analyses, often limited by shorter follow-up periods or incomplete accounting for post-trial screening, frequently misinterpreted this initial surge as a permanent increase in diagnoses, thus inflating overdiagnosis estimates.
The researchers meticulously compared breast cancer incidence at matching points in time, both in the historical randomized trials and in Denmark’s routine screening programs. This comparative approach enabled them to assess whether the observed patterns were consistent across different contexts and, more importantly, what those similarities or differences might reveal about the true scale of overdiagnosis. "Taken together, we believe some previous high estimates of overdiagnosis, which influenced screening guidelines and communication, were based on evidence before trial data had fully matured," commented Matejka Rebolj, Senior Epidemiologist at Queen Mary University of London. "When interpreted in their full temporal context, randomized trial data are consistent with overdiagnosis of less than five percent, rather than with estimates nearing 50%." This conclusion represents a paradigm shift, effectively challenging decades of widely accepted figures.
Unpacking Overdiagnosis: Definition and Nuances
To fully appreciate the study’s significance, it’s vital to understand the precise definition of overdiagnosis. Overdiagnosis occurs when screening detects a breast cancer that would never have become life-threatening or caused symptoms during a woman’s natural lifetime. In such cases, without screening, the woman would never have known that the cancer was present, living her life unaffected by its existence.
The definition can also extend to include women who die from another, unrelated cause shortly after receiving a breast cancer diagnosis through screening. In these specific scenarios, screening may have offered little to no tangible benefit because the woman’s poor overall health or limited life expectancy meant that finding and treating the breast cancer was unlikely to improve her health outcomes or extend her life. This aspect of the definition highlights the delicate balance between early detection and patient-centered care, particularly in older or co-morbid populations. The concern with overdiagnosis has always been the potential for harm from unnecessary medical interventions, including the psychological burden of a cancer diagnosis, the physical side effects of treatment, and the financial costs to healthcare systems.
The Critical Role of Timing in Shifting the Numbers
A central tenet of the new analysis is the understanding that screening fundamentally alters the timing of a cancer diagnosis, rather than solely creating "new" cancers. When mammography screening is introduced into a population, it leads to an initial, observable surge in the number of breast cancer diagnoses. This is because screening effectively brings forward the detection of cancers that would eventually have become clinically apparent even without screening (lead-time bias), as well as detecting slow-growing cancers that might never have progressed (overdiagnosis).
The critical insight is that if a study’s follow-up period concludes before enough time has elapsed for this initial surge to be balanced by a subsequent decline in diagnoses (as those "earlier detected" cancers would no longer appear later), researchers may incorrectly attribute a portion of this early increase to overdiagnosis. Furthermore, estimates can be significantly distorted when women initially assigned to a "control" or unscreened group subsequently gain access to and participate in screening programs themselves, effectively contaminating the control arm and blurring the true effect of screening.
The new analysis meticulously accounts for these complex timing effects, as well as the varying exposure to screening within both the trial and control groups, and the overall duration of follow-up. By doing so, it suggests that when these crucial factors are appropriately considered, the estimates of how often mammography identifies cancers that would otherwise never have caused a problem are substantially lower than previously believed. This methodological rigor in re-interpreting decades-old trial data provides a more robust and accurate basis for assessing the true extent of overdiagnosis.
Implications for Public Health Policy and Screening Guidelines
The findings of this study carry profound implications for public health policy, the development of screening guidelines, and the communication strategies employed by healthcare providers worldwide. For years, the high estimates of overdiagnosis contributed to divergent recommendations among different professional bodies. For instance, while some organizations maintained recommendations for regular screening starting at age 40 or 50, others emphasized the need for individual risk assessment and shared decision-making, partly due to the perceived high risk of overdiagnosis.
With the revised estimate of overdiagnosis falling below 5%, the argument for the net benefit of population-based breast cancer screening becomes considerably stronger. This could lead to a greater consensus among international health organizations and a more unified approach to screening guidelines. It reinforces the position that the life-saving benefits of early breast cancer detection significantly outweigh the much smaller risk of overdiagnosis.
From a resource allocation perspective, a clearer understanding of overdiagnosis helps justify continued investment in and expansion of screening programs. Public health systems grappling with finite resources need accurate data to ensure that interventions deliver maximum benefit with minimal harm. This study provides crucial evidence to support the continued prominence of mammography as a vital tool in cancer control strategies.
What Overdiagnosis Means for Women: Empowering Informed Decisions
Understanding both the benefits and potential downsides of screening is paramount for women making informed decisions about whether to participate in breast cancer screening programs. The persistent narrative of high overdiagnosis rates could understandably lead to hesitation or anxiety among women invited for screening, fearing unnecessary interventions or the psychological burden of a "false" cancer diagnosis.
Professor Njor offered a reassuring perspective: "Most women will not develop breast cancer, but with this study we can now be reassured that the benefits of detecting breast cancer early and preventing premature death will outweigh the small risk of unnecessary treatment." This statement underscores the primary goal of screening: to reduce breast cancer mortality by identifying treatable cancers at an early stage. The reduction in the estimated overdiagnosis rate strengthens this message of net benefit.
The study’s authors express hope that these findings will provide a more realistic framework for interpreting the evidence, enabling healthcare providers to better inform women when they are invited for screening. Clear, balanced, and evidence-based communication is essential. It empowers women to make choices aligned with their personal values and understanding of the risks and benefits. Reducing the emphasis on inflated overdiagnosis figures can alleviate undue fear and promote greater participation in life-saving screening initiatives.
Looking Ahead: The Future of Breast Cancer Screening Research
While this study provides significant clarity on a long-standing debate, the field of breast cancer screening continues to evolve. Research efforts are ongoing to further refine screening modalities, improve diagnostic accuracy, and ultimately minimize any remaining risks, including overdiagnosis. Advancements in imaging technologies, such as 3D mammography (tomosynthesis), and the integration of artificial intelligence (AI) in radiology, hold promise for more precise detection and differentiation of aggressive versus indolent cancers.
The concept of personalized screening, where a woman’s individual risk factors (genetics, family history, breast density) are used to tailor her screening regimen, is also gaining traction. Such approaches aim to optimize the balance of benefits and harms for each individual, potentially further reducing the incidence of overdiagnosis while maintaining or even improving mortality reduction. This new analysis provides a robust foundation upon which future research and policy developments can confidently build, reinforcing the importance of mammography as a cornerstone of women’s health.
The researchers performed a new, meticulous analysis of existing mammography screening research, encompassing all eight randomized trials in this field: the New York Health Insurance Plan, Malmö, Two-County, Edinburgh, the Canadian National Breast Screening Study, Stockholm, Gothenburg, and UK Age. Two regional screening programs in Denmark served as a crucial real-world reference. The team examined both invasive breast cancer and ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer that has frequently been at the center of overdiagnosis discussions.
When reassessing the earlier trials, the team focused on three critical factors that can significantly influence estimates of overdiagnosis: the duration of follow-up after screening, the extent of screening exposure in both the intervention and control groups (including post-trial screening), and the methods used to estimate lead time. After taking these intricate differences in screening exposure and follow-up into account, the researchers concluded that overdiagnosis may be substantially less common than earlier, often cited, estimates suggested.
This research was made possible through the dedicated support of various organizations. Casper Urth Pedersen is supported by the Novo Nordisk Foundation (reference: NNF22OC0076184), and Matejka Rebolj is supported by Cancer Research UK (reference: C8162/A29083). Their contributions underscore the collaborative and rigorous nature of scientific inquiry aimed at improving public health outcomes.
